Vaccines are effective in decreasing hospitalization and deaths from COVID-19 infection but the emergence of viral variants of concern may diminish their efficacy. A study publishing Dec. 2 in PLOS…
In a recent phase 2b/3 clinical trial, a third mRNA vaccine against COVID-19 — known as CVnCoV and developed by CureVac — reported approximately 48 percent efficacy against symptomatic disease.…
In many parts of the world, the supply of COVID-19 vaccines continues to lag behind the demand. While most vaccines are designed as a two-dose regimen, some countries, like Canada,…
People who had received a first dose of the Oxford-AstraZeneca COVID-19 vaccine and received an mRNA vaccine for their second dose had a lower risk of infection compared to people…
Researchers from The University of Tokyo Institute of Industrial Science have found that infection with the measles virus activates not one but two different branches of the innate immune system.…
